<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-97357" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Botulinum Toxin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padda</surname>
            <given-names>Inderbir S.</given-names>
          </name>
          <aff>Richmond University Medical Center/Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tadi</surname>
            <given-names>Prasanna</given-names>
          </name>
          <aff>Asram Medical College, Eluru, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Inderbir Padda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prasanna Tadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-97357.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Botulinum toxin is a medication used to manage and treat therapeutic and cosmetic purposes. Medicinal uses include chronic migraine, spastic disorders, cervical dystonia, and detrusor hyperactivity. Botulinum toxin is in the neurotoxin class of medications. This activity reviews the indications, action, and contraindications for botulinum toxin therapy as a valuable agent for therapeutic and cosmetic treatment in the clinical setting. This activity discusses&#x000a0;the mechanism of action, adverse event profile, and other key factors pertinent to healthcare team members in the management of patients with spastic muscle disorders and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate candidates for botulinum toxin therapy based on clinical indications, patient history, and physical examination findings.</p></list-item><list-item><p>Screen patients for contraindications, potential risks, and allergies related to botulinum toxin treatment.</p></list-item><list-item><p>Assess treatment response and patient satisfaction through objective measures and patient-reported outcomes.</p></list-item><list-item><p>Communicate with patients about the expected outcomes, possible side effects, and proper post-treatment care for botulinum toxin therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=97357&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=97357">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-97357.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Botulinum toxin is a highly potent neurotoxin produced by the <italic toggle="yes">Clostridium botulinum</italic>.<xref ref-type="bibr" rid="article-97357.r1">[1]</xref> Clinicians have used this neurotoxin in practice since late 1970.<xref ref-type="bibr" rid="article-97357.r2">[2]</xref>&#x000a0;<italic toggle="yes">Clostridium botulinum</italic> is a spore-forming, gram-positive, anaerobic bacterium.<xref ref-type="bibr" rid="article-97357.r1">[1]</xref>&#x000a0;Botulinum neurotoxins are&#x000a0;a group of&#x000a0;7 serotypes A-G, prepared in&#x000a0;4 types for practical use.<xref ref-type="bibr" rid="article-97357.r3">[3]</xref><xref ref-type="bibr" rid="article-97357.r4">[4]</xref>&#x000a0;Serotype A&#x000a0;is&#x000a0;&#x000a0;3 of these; serotype B is 1.<xref ref-type="bibr" rid="article-97357.r4">[4]</xref>&#x000a0;</p>
        <p>As mentioned, there are&#x000a0;3 forms of serotype A and&#x000a0;1 form of serotype B.<xref ref-type="bibr" rid="article-97357.r4">[4]</xref>&#x000a0;All&#x000a0;4 types are approved globally for treating spasmodic torticollis, which can cause fixed head posturing or abnormal head movements. The three serotype A products have approval for focal dystonia that can affect the eye, causing irregular eyelid twitching or closure.<xref ref-type="bibr" rid="article-97357.r4">[4]</xref>&#x000a0;</p>
        <p>Botulinum toxin is FDA-approved to treat migraines, which to date is the only chronic condition approved for its use. The therapeutic effect derives from minimizing muscle tension and enhancing muscle relaxation.<xref ref-type="bibr" rid="article-97357.r5">[5]</xref>&#x000a0;The neurotoxin formulation of botulinum toxin A is among the popular cosmetic procedures in America.<xref ref-type="bibr" rid="article-97357.r5">[5]</xref>&#x000a0;</p>
        <p>Aesthetically, all three serotypes A&#x000a0;forms are used for wrinkles and facial lines.<xref ref-type="bibr" rid="article-97357.r4">[4]</xref>&#x000a0;The toxin has also shown effectiveness in other medical conditions, such as strabismus and hypersalivation.<xref ref-type="bibr" rid="article-97357.r2">[2]</xref><xref ref-type="bibr" rid="article-97357.r1">[1]</xref><xref ref-type="bibr" rid="article-97357.r6">[6]</xref>&#x000a0;The neurotoxin is a beneficial alternative pain remedy and should be considered for those that do not yield desirable results to opioid treatment.<xref ref-type="bibr" rid="article-97357.r5">[5]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold><bold>Chronic migraine:&#x000a0;</bold></bold>For&#x000a0;adult patients with chronic migraine who have migraines that occur 15 days or more per month with headaches lasting 4 hours a day or longer,&#x000a0;botulinum toxin&#x000a0;is indicated for the prophylaxis of headaches. However, safety and efficacy have not been established for the prophylaxis of episodic migraine for adult patients who have migraines that occur 14 headache days or&#x000a0;less per month in seven placebo-controlled studies.<xref ref-type="bibr" rid="article-97357.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Cervical dystonia:</bold>&#x000a0; Botulinum toxin&#x000a0;is indicated for treating adults with cervical dystonia as it reduces the severity of abnormal head position and neck pain associated with cervical dystonia.<xref ref-type="bibr" rid="article-97357.r4">[4]</xref><xref ref-type="bibr" rid="article-97357.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Blepharospasm and strabismus: </bold>Botulinum toxin is recommended for patients aged 12 years and&#x000a0;older to treat strabismus and blepharospasm caused by dystonia. This includes benign essential blepharospasm or VII nerve disorders.<xref ref-type="bibr" rid="article-97357.r8">[8]</xref><xref ref-type="bibr" rid="article-97357.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><bold><bold>Primary axillary hyperhidrosis: </bold></bold>Botulinum&#x000a0;toxin is indicated for severe primary axillary hyperhidrosis treatment inadequately managed with topical agents. However, the safety and effectiveness of botulinum toxin have not been established for hyperhidrosis in other body areas. Also, the safety and efficacy of botulinum toxin have not been established in pediatric patients under age 18 to treat axillary hyperhidrosis.<xref ref-type="bibr" rid="article-97357.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Adult bladder dysfunction:</bold>&#x000a0;For adults who do not respond adequately to or are intolerant of anticholinergic medication, botulinum toxin is indicated for overactive bladder treatment with symptoms of urgency, frequency, and urge urinary incontinence. Botulinum toxin is also indicated for urinary incontinence treatment in these adults due to detrusor overactivity associated with a neurologic condition like MS or SCI.<xref ref-type="bibr" rid="article-97357.r7">[7]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Pediatric detrusor overactivity associated with a neurologic condition: </bold>For pediatric&#x000a0;patients over the age of 5 years who do not have an adequate response to or are intolerant of anticholinergic medication, botulinum toxin is indicated for the treatment of neurogenic detrusor overactivity.</p>
          </list-item>
          <list-item>
            <p><bold><bold>Spasticity:&#x000a0;</bold></bold>For patients 2 years of age and older, botulinum toxin is indicated for the treatment of spasticity. However, botulinum toxin has not been shown to&#x000a0;enhance&#x000a0;the range of motion at a joint affected by upper extremity functional abilities or a fixed contracture.<xref ref-type="bibr" rid="article-97357.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Botulinum toxin cosmetic:&#x000a0; </bold>Cosmetic botulinum toxin is indicated in adult patients for the temporary appearance improvement in the moderate to severe glabellar lines associated with corrugator and procerus muscle activity, lateral canthal lines associated with orbicularis oculi activity, and forehead lines associated with frontalis muscle activity.<xref ref-type="bibr" rid="article-97357.r9">[9]</xref><xref ref-type="bibr" rid="article-97357.r5">[5]</xref><xref ref-type="bibr" rid="article-97357.r8">[8]</xref><xref ref-type="bibr" rid="article-97357.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Use</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Neurogenic thoracic outlet syndrome&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Epicondylitis</p>
          </list-item>
          <list-item>
            <p>Post-stroke pain</p>
          </list-item>
          <list-item>
            <p>Post-herpetic neuralgia</p>
          </list-item>
          <list-item>
            <p>Diabetic neuropathy</p>
          </list-item>
          <list-item>
            <p>Trigeminal neuralgia</p>
          </list-item>
          <list-item>
            <p>Neuropathic pain</p>
          </list-item>
          <list-item>
            <p>Spinal cord injury</p>
          </list-item>
          <list-item>
            <p>Myofascial pain</p>
          </list-item>
          <list-item>
            <p>Bladder pain&#x000a0;<xref ref-type="bibr" rid="article-97357.r6">[6]</xref><xref ref-type="bibr" rid="article-97357.r10">[10]</xref><xref ref-type="bibr" rid="article-97357.r11">[11]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-97357.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The potent zinc proteinase neurotoxin binds to extracellular receptors on cholinergic nerve terminals, cleaving one of the three (SNARE) soluble&#x000a0;<italic toggle="yes">N</italic>-ethylmaleimide-sensitive factor attachment receptor proteins. This action causes reversible inhibition of the release of acetylcholine by presynaptic vesicles intracellularly, leading to a transient restraint of neurotransmitter release at the neuromuscular junction.<xref ref-type="bibr" rid="article-97357.r2">[2]</xref><xref ref-type="bibr" rid="article-97357.r3">[3]</xref><xref ref-type="bibr" rid="article-97357.r6">[6]</xref><xref ref-type="bibr" rid="article-97357.r12">[12]</xref><xref ref-type="bibr" rid="article-97357.r13">[13]</xref>&#x000a0;</p>
        <p>SNARE proteins also play an identified role in neurons&#x000a0;that release glutamate and substance R. Their actions are to release bradykinin, prostaglandins, histamine, and serotonin, which are proinflammatory mediators. The inhibition of these constituents may account for its possible treatment in chronic pain disorders, migraines, and neuralgias.<xref ref-type="bibr" rid="article-97357.r7">[7]</xref></p>
      </sec>
      <sec id="article-97357.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Botulinum toxin has a longer duration of action once administered; it takes approximately two weeks to thoroughly develop efficacy and the last three to five months in cosmetic practice.<xref ref-type="bibr" rid="article-97357.r5">[5]</xref><xref ref-type="bibr" rid="article-97357.r14">[14]</xref>&#x000a0;Botulinum toxin's therapeutic uses&#x000a0;on autonomic neurons for hyperhidrosis or overactive bladder have a significantly more&#x000a0;prolonged effect, ranging from six to nine months.<xref ref-type="bibr" rid="article-97357.r6">[6]</xref>&#x000a0;</p>
        <p>
<bold>FDA-Approved Preparations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>OnabotulinumtoxinA&#x000a0;</p>
          </list-item>
          <list-item>
            <p>AbobotulinumtoxinA</p>
          </list-item>
          <list-item>
            <p>IncobotulinumtoxinA&#x000a0;</p>
          </list-item>
          <list-item>
            <p>RimabotulinumtoxinB&#x000a0;<xref ref-type="bibr" rid="article-97357.r15">[15]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Dilution</bold>
</p>
        <p>OnabotulinumtoxinA suggested dilution:</p>
        <list list-type="bullet">
          <list-item>
            <p>100 U of powder form in 1 to 8 mL of saline.<xref ref-type="bibr" rid="article-97357.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>AbobotulinumtoxinA suggested dilution:</p>
        <list list-type="bullet">
          <list-item>
            <p>300 U of powder form in 0.6 to 2.5 mL of saline.<xref ref-type="bibr" rid="article-97357.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>The pharmaceutical form is packaged and distributed in powder form for all four preparations.<xref ref-type="bibr" rid="article-97357.r7">[7]</xref>&#x000a0;Diluting the powder pharmaceutical form of botulinum toxin requires caution if more significant dilution with saline is desired.&#x000a0;This dilution may cause spread to unwanted regions&#x000a0;and yield suboptimal results; it can also cause unwanted adverse effects, such as eyelid ptosis.<xref ref-type="bibr" rid="article-97357.r7">[7]</xref>&#x000a0;</p>
        <p>
<bold>FDA-Approved Dose for Aesthetic Glabellar Lines</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>AbobotulinumtoxinA&#x000a0;50 U</p>
          </list-item>
          <list-item>
            <p>OnabotulinumtoxinA cosmetic 20 U</p>
          </list-item>
          <list-item>
            <p>IncobotulinumtoxinA 20 U&#x000a0;<xref ref-type="bibr" rid="article-97357.r16">[16]</xref></p>
          </list-item>
        </list>
        <p>FDA-approved labels advise against performing potency conversions.<xref ref-type="bibr" rid="article-97357.r15">[15]</xref>&#x000a0;Injecting botulinum toxin into distinct muscles causes&#x000a0;flaccid paralysis and muscle relaxation.<xref ref-type="bibr" rid="article-97357.r11">[11]</xref>&#x000a0;Aesthetically, this can diminish wrinkles by confined muscle relaxation and smoothing the overlying dermis.<xref ref-type="bibr" rid="article-97357.r14">[14]</xref></p>
        <p><bold>Pharmacokinetics</bold>At the recommended doses, botulinum toxin is undetectable in the peripheral blood following intramuscular injection using currently available analytical technology.</p>
        <p>
<bold>Specific Patients Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0; The manufacturer provides no specific dose adjustment guidance for patients with hepatic impairment.</p>
        <p><bold>Renal impairment:</bold>&#x000a0; The manufacturer provides no specific dose adjustment guidance for patients with&#x000a0;renal impairment.</p>
        <p><bold>Pregnancy:</bold>&#x000a0; Botulinum toxin&#x000a0;is considered a pregnancy category C drug.&#x000a0;No studies or adequate data from postmarketing surveillance related to the developmental risk associated with using&#x000a0;botulinum toxin in pregnant women exist.</p>
        <p><bold>Breastfeeding:</bold>&#x000a0;The manufacturer's label does not indicate whether botulinum toxin is present in human milk and its effects on milk production and the breastfed infant. Therefore,&#x000a0;clinicians must weigh the benefits of breastfeeding against the need for botulinum toxin treatment for the mother. Additionally, any potential adverse effects on the breastfed infant from botulinum toxin or the underlying conditions of the mother should be carefully considered before initiating treatment.</p>
        <p><bold>Pediatric patients: </bold>Based on indication, the following&#x000a0;guidance&#x000a0;is provided&#x000a0;for using botulinum toxin in pediatric patients.&#x000a0;</p>
        <p><bold>Overactive Bladder:&#x000a0;</bold>Research has not determined whether the treatment is safe and effective for individuals&#x000a0;younger than 18.</p>
        <p><bold>Detrusor overactivity associated with a neurologic condition:</bold> The safety and effectiveness have been established in pediatric patients aged 5 years and older who have an inadequate response to or are intolerant of anticholinergic medication for the use of botulinum toxin for detrusor overactivity associated with a neurologic condition.&#x000a0;Safety and effectiveness have not been established&#x000a0;in patients&#x000a0;younger than 5 years for patients with NDO.&#x000a0;</p>
        <p><bold>Prophylaxis of headaches in chronic migraine:</bold>&#x000a0;No determination has been made whether the treatment is safe and effective for individuals&#x000a0;younger than&#x000a0;the age of 18.&#x000a0;</p>
        <p><bold>Spasticity:</bold>&#x000a0;Studies and clinical experience have established that the treatment is safe and effective in pediatric patients&#x000a0;aged&#x000a0;2 to 17.</p>
        <p><bold>Axillary hyperhidrosis:</bold> No determination has been made&#x000a0;whether the treatment is safe and effective for individuals&#x000a0;younger than 18.</p>
        <p><bold>Cervical dystonia:</bold> No determination has been made&#x000a0;whether the treatment is safe and effective for individuals&#x000a0;younger than&#x000a0;16.</p>
        <p><bold>Blepharospasm and strabismus:</bold> No determination has been made&#x000a0;whether the treatment is safe and effective for individuals&#x000a0;younger than 12.</p>
        <p><bold>Older&#x000a0;Patients: </bold>The safety profiles of geriatric patients and those&#x000a0;younger than 65 years old were found to be similar in placebo-controlled clinical studies of botulinum toxin for spasticity treatment. In clinical studies for all indications except overactive bladder, there were no significant differences in safety profiles between&#x000a0;older&#x000a0;and adult patients&#x000a0;younger than 65. However, in a clinical study for overactive bladder, patients&#x000a0;older than 65 experienced more UTI and urinary retention adverse reactions than younger patients in both the placebo and botulinum toxin groups. Overall, there were no significant safety profile differences&#x000a0;in patients 65 years and older and those younger than&#x000a0;65 following botulinum toxin treatment.</p>
      </sec>
      <sec id="article-97357.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects are frequently moderate and self-limited.<xref ref-type="bibr" rid="article-97357.r7">[7]</xref>&#x000a0;Therapeutic use of botulinum toxin reported more&#x000a0;concerning adverse effects than&#x000a0;its use in cosmetic practice; this may be due to the higher dosing required for therapeutic&#x000a0;applications and possible complicated underlying conditions.<xref ref-type="bibr" rid="article-97357.r8">[8]</xref>&#x000a0;</p>
        <p>Among minor complications, bruising, edema, or pain at the injection site can develop during aesthetic use.<xref ref-type="bibr" rid="article-97357.r7">[7]</xref><xref ref-type="bibr" rid="article-97357.r14">[14]</xref>&#x000a0;Flu-like symptoms can also occur. More uncommon complications include blepharoptosis and eyebrow ptosis; these adverse events depend&#x000a0;on the injector.<xref ref-type="bibr" rid="article-97357.r14">[14]</xref>&#x000a0;</p>
        <p>Eyelid ptosis transpires with the introduction of botulinum toxin is introduced into the glabella, procerus, and corrugator muscles with unintended dispersion into the levator orbicularis muscle.<xref ref-type="bibr" rid="article-97357.r7">[7]</xref>&#x000a0;These unfavorable effects can last up to&#x000a0;3 months.<xref ref-type="bibr" rid="article-97357.r7">[7]</xref>&#x000a0;</p>
        <p>As the technique and skill for injections improve, complications decrease.<xref ref-type="bibr" rid="article-97357.r14">[14]</xref>&#x000a0;Allergic reactions are amongst the rare reported adverse effects. Symptoms may range from trivial to more severe rashes, and systemic anaphylaxis may also occur.<xref ref-type="bibr" rid="article-97357.r7">[7]</xref></p>
        <p>Other complications include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Infection</p>
          </list-item>
          <list-item>
            <p>Cocked eyebrow</p>
          </list-item>
          <list-item>
            <p>Ectropion</p>
          </list-item>
          <list-item>
            <p>Decreased strength of eye closure</p>
          </list-item>
          <list-item>
            <p>Xerophthalmia&#x000a0;<xref ref-type="bibr" rid="article-97357.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-97357.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Botulinum toxin contraindications include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Keloidal scarring</p>
          </list-item>
          <list-item>
            <p>Neuromuscular disorders&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Botulinum toxin allergies</p>
          </list-item>
          <list-item>
            <p>Body dysmorphic disorder</p>
          </list-item>
          <list-item>
            <p>Pregnancy</p>
          </list-item>
          <list-item>
            <p>Breastfeeding</p>
          </list-item>
          <list-item>
            <p>Amyotrophic lateralizing sclerosis myopathies&#x000a0;<xref ref-type="bibr" rid="article-97357.r14">[14]</xref><xref ref-type="bibr" rid="article-97357.r17">[17]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Boxed Warning</bold>
</p>
        <p>Based on postmarketing reports, it has been observed that the impact of botulinum toxin and all related products may extend beyond the injection site and lead to symptoms that are in line with botulinum toxin effects. These may include asthenia, diplopia, ptosis, dysphagia, generalized muscle weakness,&#x000a0; dysphonia, dysarthria, breathing difficulties, and urinary incontinence. These symptoms&#x000a0;may occur&#x000a0;hours to weeks after injection. Breathing and swallowing difficulties can be life-threatening, and there have been reports of death.</p>
        <p>Symptoms are more likely to occur in children receiving treatment for spasticity. Still, adults treated for spasticity and other conditions may also experience symptoms, especially if they have an underlying condition that makes them more susceptible.&#x000a0;Cases of the spread of effect have been reported&#x000a0;in unapproved uses&#x000a0;and approved indications at doses comparable to those used to treat spasticity and cervical dystonia and at lower doses.</p>
      </sec>
      <sec id="article-97357.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The continuation of the paralysis and muscle relaxation effect is based on the temporary restraint of neurotransmitter release. The half-life differs among the serotypes and relies on when the SNARE protein regains function and releases the neurotransmitter acetylcholine. Studies suggest that&#x000a0;botulinum neurotoxin serotype A has the&#x000a0;most prolonged half-life.<xref ref-type="bibr" rid="article-97357.r7">[7]</xref></p>
      </sec>
      <sec id="article-97357.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The human LD50&#x000a0;for inhalation botulism is 1 to 3 ng/kg body mass.<xref ref-type="bibr" rid="article-97357.r18">[18]</xref>&#x000a0;LD50 is a lethal dose that would cause fatality in 50% of people receiving an application of the drug.&#x000a0;As a bioweapon, botulinum toxin can be transmitted by airborne or foodborne methods. Toxicity will induce symptoms 12 hours to 3 days following exposure. Presenting symptoms include difficulty swallowing, hoarseness in voice, slurred or slow speech, double vision, and descending flaccid paralysis.<xref ref-type="bibr" rid="article-97357.r19">[19]</xref><xref ref-type="bibr" rid="article-97357.r13">[13]</xref></p>
        <p>
<bold>Toxicity Treatment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Antitoxin</p>
          </list-item>
          <list-item>
            <p>Vaccine</p>
          </list-item>
          <list-item>
            <p>F(ab')2 immune fragment therapies&#x000a0;<xref ref-type="bibr" rid="article-97357.r18">[18]</xref><xref ref-type="bibr" rid="article-97357.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>These treatments are in addition to supportive therapy.<xref ref-type="bibr" rid="article-97357.r18">[18]</xref></p>
      </sec>
      <sec id="article-97357.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Botulinum toxin is an FDA-approved medication indicated for therapeutic and cosmetic treatments. Managing the care of patients prescribed botulinum toxin for therapeutic purposes requires excellent communication between the patient and an interprofessional team of healthcare providers. These providers include a primary care physician or advanced practice practitioner, specialists that can consist of a neurologist, a gynecologist, a urologist, and others, and a nurse with their respective therapeutic uses for chronic migraine, post-stroke pain, cervical dystonia, and urinary incontinence from detrusor overactivity.</p>
        <p>Meanwhile, cosmetic treatments require technique and skill for facial injections, which a highly skilled nurse or clinician can administer in an outpatient clinic setting. The recommendation is that site injections are under the clinician's guidance to assure patient safety if complications arise. The primary care provider, specialist, and nursing staff should be familiar with botulinum toxin, its implications, and adverse effects. The clinicians and nurses require excellent patient rapport, and the patient needs thorough education on the treatment and symptoms of adverse effects. Botulinum toxin injections require routine checkups every&#x000a0;3 to 5 months to optimize desired outcomes.<xref ref-type="bibr" rid="article-97357.r21">[21]</xref><xref ref-type="bibr" rid="article-97357.r22">[22]</xref><xref ref-type="bibr" rid="article-97357.r23">[23]</xref><xref ref-type="bibr" rid="article-97357.r24">[24]</xref>&#x000a0;The interprofessional team approach, customized to the particular indication, enhances patient outcomes with botulinum toxin while mitigating potential adverse events.</p>
      </sec>
      <sec id="article-97357.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=97357&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=97357">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/97357/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=97357">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-97357.s11">
        <title>References</title>
        <ref id="article-97357.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nigam</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Nigam</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin.</article-title>
            <source>Indian J Dermatol</source>
            <year>2010</year>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-14</page-range>
            <pub-id pub-id-type="pmid">20418969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahant</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Clouston</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Lorentz</surname>
                <given-names>IT</given-names>
              </name>
            </person-group>
            <article-title>The current use of botulinum toxin.</article-title>
            <source>J Clin Neurosci</source>
            <year>2000</year>
            <month>Sep</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>389</fpage>
            <page-range>389-94</page-range>
            <pub-id pub-id-type="pmid">10942658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Parmar</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin.</article-title>
            <source>Appl Environ Microbiol</source>
            <year>2018</year>
            <month>Dec</month>
            <day>15</day>
            <volume>84</volume>
            <issue>24</issue>
            <pub-id pub-id-type="pmid">30389764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bentivoglio</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Del Grande</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Petracca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ialongo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ricciardi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clinical differences between botulinum neurotoxin type A and B.</article-title>
            <source>Toxicon</source>
            <year>2015</year>
            <month>Dec</month>
            <day>01</day>
            <volume>107</volume>
            <issue>Pt A</issue>
            <fpage>77</fpage>
            <page-range>77-84</page-range>
            <pub-id pub-id-type="pmid">26260691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Willett</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Thompkins</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hermann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ramanathan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cornett</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>15</fpage>
            <pub-id pub-id-type="pmid">26879873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Botulinum Toxin for the Treatment of Neuropathic Pain.</article-title>
            <source>Toxins (Basel)</source>
            <year>2017</year>
            <month>Aug</month>
            <day>24</day>
            <volume>9</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">28837075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walker</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Dayan</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Comparison and overview of currently available neurotoxins.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>31</fpage>
            <page-range>31-9</page-range>
            <pub-id pub-id-type="pmid">24587850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cot&#x000e9;</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Polder</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Walton</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>407</fpage>
            <page-range>407-15</page-range>
            <pub-id pub-id-type="pmid">16112345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hong</surname>
                <given-names>SO</given-names>
              </name>
            </person-group>
            <article-title>Cosmetic Treatment Using Botulinum Toxin in the Oral and Maxillofacial Area: A Narrative Review of Esthetic Techniques.</article-title>
            <source>Toxins (Basel)</source>
            <year>2023</year>
            <month>Jan</month>
            <day>17</day>
            <volume>15</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">36828397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Godoy</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Donahue</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Torriani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Botulinum Toxin Injections in Musculoskeletal Disorders.</article-title>
            <source>Semin Musculoskelet Radiol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>441</fpage>
            <page-range>441-452</page-range>
            <pub-id pub-id-type="pmid">28002866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luvisetto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gazerani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cianchetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pavone</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders.</article-title>
            <source>Toxins (Basel)</source>
            <year>2015</year>
            <month>Sep</month>
            <day>23</day>
            <volume>7</volume>
            <issue>9</issue>
            <fpage>3818</fpage>
            <page-range>3818-44</page-range>
            <pub-id pub-id-type="pmid">26404377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dressler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saberi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Barbosa</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin: mechanisms of action.</article-title>
            <source>Arq Neuropsiquiatr</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>180</fpage>
            <page-range>180-5</page-range>
            <pub-id pub-id-type="pmid">15830090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhaked</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin: bioweapon &#x00026; magic drug.</article-title>
            <source>Indian J Med Res</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>132</volume>
            <issue>5</issue>
            <fpage>489</fpage>
            <page-range>489-503</page-range>
            <pub-id pub-id-type="pmid">21149997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Small</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin injection for facial wrinkles.</article-title>
            <source>Am Fam Physician</source>
            <year>2014</year>
            <month>Aug</month>
            <day>01</day>
            <volume>90</volume>
            <issue>3</issue>
            <fpage>168</fpage>
            <page-range>168-75</page-range>
            <pub-id pub-id-type="pmid">25077722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zakin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Evidence on botulinum toxin in selected disorders.</article-title>
            <source>Toxicon</source>
            <year>2018</year>
            <month>Jun</month>
            <day>01</day>
            <volume>147</volume>
            <fpage>134</fpage>
            <page-range>134-140</page-range>
            <pub-id pub-id-type="pmid">29408357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Field</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Splevins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Picaut</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van der Schans</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Langenberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Noort</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>AbobotulinumtoxinA (Dysport<sup>&#x000ae;</sup>), OnabotulinumtoxinA (Botox<sup>&#x000ae;</sup>), and IncobotulinumtoxinA (Xeomin<sup>&#x000ae;</sup>) Neurotoxin Content and Potential Implications for Duration of Response in Patients.</article-title>
            <source>Toxins (Basel)</source>
            <year>2018</year>
            <month>Dec</month>
            <day>13</day>
            <volume>10</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">30551641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kattimani</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tiwari</surname>
                <given-names>RVC</given-names>
              </name>
              <name>
                <surname>Gufran</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wasan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shilpa</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Khader</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Botulinum Toxin Application in Facial Esthetics and Recent Treatment Indications (2013-2018).</article-title>
            <source>J Int Soc Prev Community Dent</source>
            <year>2019</year>
            <season>Mar-Apr</season>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-105</page-range>
            <pub-id pub-id-type="pmid">31058058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horowitz</surname>
                <given-names>BZ</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin.</article-title>
            <source>Crit Care Clin</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>825</fpage>
            <page-range>825-39, viii</page-range>
            <pub-id pub-id-type="pmid">16168317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnon</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Schechter</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Inglesby</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Ascher</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Eitzen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Hauer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Layton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lillibridge</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Osterholm</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>O'Toole</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perl</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Swerdlow</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Tonat</surname>
                <given-names>K</given-names>
              </name>
              <collab>Working Group on Civilian Biodefense</collab>
            </person-group>
            <article-title>Botulinum toxin as a biological weapon: medical and public health management.</article-title>
            <source>JAMA</source>
            <year>2001</year>
            <month>Feb</month>
            <day>28</day>
            <volume>285</volume>
            <issue>8</issue>
            <fpage>1059</fpage>
            <page-range>1059-70</page-range>
            <pub-id pub-id-type="pmid">11209178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khouri</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Motter</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Arnon</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity.</article-title>
            <source>Vaccine</source>
            <year>2018</year>
            <month>Apr</month>
            <day>05</day>
            <volume>36</volume>
            <issue>15</issue>
            <fpage>2041</fpage>
            <page-range>2041-2048</page-range>
            <pub-id pub-id-type="pmid">29475762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castel&#x000e3;o</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Duarte</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sampaio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin type A therapy for cervical dystonia.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Dec</month>
            <day>12</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>CD003633</fpage>
            <pub-id pub-id-type="pmid">29230798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herd</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Tomlinson</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Rick</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Scotton</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ives</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxins for the prevention of migraine in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Jun</month>
            <day>25</day>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>CD011616</fpage>
            <pub-id pub-id-type="pmid">29939406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kuriyama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hayashino</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis.</article-title>
            <source>JAMA</source>
            <year>2012</year>
            <month>Apr</month>
            <day>25</day>
            <volume>307</volume>
            <issue>16</issue>
            <fpage>1736</fpage>
            <page-range>1736-45</page-range>
            <pub-id pub-id-type="pmid">22535858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97357.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jia</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Adverse Events of Botulinum Toxin Type A in Facial Rejuvenation: A Systematic Review and Meta-Analysis.</article-title>
            <source>Aesthetic Plast Surg</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>769</fpage>
            <page-range>769-77</page-range>
            <pub-id pub-id-type="pmid">27495260</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
